Novo Nordisk | NVO - Selling And Administration Expenses


Novo Nordisk reported DKK2.86B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Bausch Health Companies USD 801M 6M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Merck USD 2.85B 215M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Novartis USD 3.31B 134M Sep/2025
Novo Nordisk DKK 17.44B 1.41B Dec/2025
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Phibro Animal Health USD 76.34M 10.54M Dec/2024
Prestige Brands USD 29.67M 1.64M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
Zoetis USD 619M 40M Dec/2025